Literature DB >> 17085857

Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice.

Jarogniew J Luszczki1, Marek Zuchora, Katarzyna M Sawicka, Justyna Kozińska, Stanisław J Czuczwar.   

Abstract

This study examines the effect of acute administration of caffeine sodium benzoate (CAF) on the anticonvulsant action of four conventional antiepileptic drugs (AEDs: clonazepam - CZP, ethosuximide - ETS, phenobarbital - PB and valproate - VPA) against pentetrazole (PTZ)-induced clonic seizures in mice. The results indicate that CAF at a dose of 92.4 mg/kg significantly reduced the threshold for PTZ-induced clonic seizures in mice from 69.5 to 51.7 mg/kg (p<0.05), being ineffective at lower doses of 69.3 and 46.2 mg/kg. Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively. In this case, no pharmacokinetic changes in total brain ETS concentrations after systemic ip administration of CAF (at 92.4 mg/kg) were observed, indicating a pharmacodynamic nature of interaction between ETS and CAF in the PTZ-test in mice. In contrast, CAF (at a dose of 92.4 mg/kg reducing the threshold for PTZ-induced seizures) combined with other AEDs (CZP, PB and VPA) did not affect their anticonvulsant action in the PTZ test in mice. Moreover, CAF (92.4 mg/kg) did not alter significantly total brain concentrations of the remaining AEDs (CZP, PB and VPA). The evaluation of potential acute adverse effects produced by AEDs in combination with CAF revealed that neither CAF (up to 92.4 mg/kg) administered alone nor combined with the studied drugs (at doses corresponding to their ED(50) values in the PTZ-test) affected motor performance of animals in the chimney test. In conclusion, the acute exposure to CAF may diminish the antiseizure protection offered by ETS in epileptic patients. Therefore, patients treated with ETS should avoid CAF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085857

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  7 in total

Review 1.  The Use of Caffeine by People with Epilepsy: the Myths and the Evidence.

Authors:  Prisca R Bauer; Josemir W Sander
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-14       Impact factor: 5.081

2.  Caffeine Protects Against Anticonvulsant-Induced Neurotoxicity in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Marco Sifringer; Ivo Bendix; Christoph Bührer
Journal:  Neurotox Res       Date:  2017-06-22       Impact factor: 3.911

3.  Effect of caffeine on the anticonvulsant action of pregabalin against electroconvulsions in mice.

Authors:  Roman Chwedorowicz; Krzysztof Łukawski; Grzegorz Raszewski; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2022-02-16       Impact factor: 3.024

4.  Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model.

Authors:  J J Luszczki; K Jankiewicz; M Jankiewicz; S J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2007-08-24       Impact factor: 3.575

5.  Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.

Authors:  Dorota Nieoczym; Katarzyna Socała; Jarogniew J Łuszczki; Stanisław J Czuczwar; Piotr Wlaz
Journal:  J Neural Transm (Vienna)       Date:  2012-08       Impact factor: 3.575

6.  QSAR and Molecular Docking Studies of the Inhibitory Activity of Novel Heterocyclic GABA Analogues over GABA-AT.

Authors:  Josué Rodríguez-Lozada; Erika Tovar-Gudiño; Juan Alberto Guevara-Salazar; Rodrigo Said Razo-Hernández; Ángel Santiago; Nina Pastor; Mario Fernández-Zertuche
Journal:  Molecules       Date:  2018-11-15       Impact factor: 4.411

Review 7.  Caffeine and Clinical Outcomes in Premature Neonates.

Authors:  Vasantha H S Kumar; Steven E Lipshultz
Journal:  Children (Basel)       Date:  2019-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.